AbbVie Steps Into Ring In Obesity Drug Wars

Here's How to Play AbbVie Stock as it Enters the Obesity Space
AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for the treatment of obesity, from Danish research company, Gubra. While the obesity field is greatly dominated by GLP-1 products,
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue. Click to read why ABBV is a Hold.
AbbVie steps into the obesity drug race, licensing medicine from Danish firm
The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.
AbbVie, Gubra in Obesity-Drug License Pact Potentially Worth More Than $2 Billion
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services company.
AbbVie enters obesity drug market with Danish drugmaker
AbbVie has signed a licensing deal with Gubra A/S to develop an obesity drug, marking the North Chicago company's first foray into the obesity market.
AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion.
AbbVie inked a licensing deal Monday worth up to $2.23 billion for an amylin-targeting obesity treatment from Denmark-based Gubra A/S.
AbbVie Joins Obesity Treatment Market With Up to $2.2B Licensing Deal
Key Takeaways AbbVie agreed to license a weight-loss drug in development from Danish biotech firm Gubra.AbbVie said it will ...
BioPharma Dive2d
AbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...
STAT3h
How the race for the next obesity drug is shaping up
While some drugs have fallen off, more have been added: AbbVie recently jumped into the obesity craze by licensing an ...
BioSpace7h
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
FierceBiotech2d
AbbVie pays Gubra $350M to make late play for obesity space
AbbVie is paying $350 million to join the obesity race. The outlay, plus up to $1.875 billion in milestones, has landed the ...
AbbVie price target raised to $223 from $200 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $223 from $200 and keeps a Neutral rating on the shares after the company and Gubra ...